Hydrogenology
Hydrogenology editorial study record

Therapeutic effects of hydrogen on chronic graft-versus-host disease

Qian L, Liu X, Shen J, Zhao D, Yin W. · Journal of Cellular and Molecular Medicine. 2017;21(10):2627–2630.

PreclinicalOther formsPublished 2017
Study record, not medical adviceThis page reports one source and Hydrogenology’s source-text extraction. It does not establish that molecular hydrogen is effective, safe or appropriate for any person. Human, animal and laboratory evidence must not be treated as equivalent.
Source and classification

What kind of evidence is this?

Evidence stream

Preclinical

Reported design

Controlled chronic graft-versus-host-disease mouse experiment

Research topic

Immune and inflammatory conditions

Administration classification

Other forms

Study result signal

Not reported in this record.

Outcome type

Not reported in this record.

Reported in the source

Methods at a glance

Population or model

BALB/c RAG-2 knockout mice receiving B10.D2 spleen cells to induce chronic graft-versus-host disease.

Sample

Principal survival and skin figures report n=30 across hydrogen-rich-saline and ordinary-saline conditions; per-group denominators were not printed separately in the figure legend.

Duration

Daily treatment from day 20; survival through day 60 and skin histopathology on day 55.

Intervention

Hydrogen-rich saline 5 mL/kg intraperitoneally once daily starting 20 days after transplantation.

Hydrogen form

H₂ dissolved in saline — H₂ only, not inhaled and not Brown's gas.

H₂ specification

Saline contained more than 0.6 mmol/L dissolved H₂ after preparation for 6 hours under 0.4 MPa; concentration was confirmed by gas chromatography.

H₂ flow

Not applicable — intraperitoneal saline, not gas inhalation.

O₂ delivered with H₂

No O₂ was co-delivered as part of the intervention.

Comparator

Physiological saline under the same transplantation model.

Reported, not endorsed

Outcomes and reported result

Outcomes measured

Survival, serial clinical skin-lesion score and blinded histopathological skin score.

Reported result

By day 60, 80% of H₂-treated mice survived versus 30% of untreated cGVHD mice (p<0.05). Clinical skin scores were lower, and mean pathology score on day 55 was 1.6 versus 3.8 (p<0.05).

Results-extraction completeness

The complete PubMed Central article, model, saline concentration, dose, timing, survival, skin scoring, funding and conflicts were checked.

A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.

Interpretation limits

Cautions and applicability

Design and reporting cautions

Single animal model with delayed post-transplant treatment and limited outcomes; group denominators are not clearly separated in the printed figure legend. It cannot establish efficacy in people. Funding came from the Innovative Cultivation Foundation of Chinese Navy General Hospital (CXPY201603); authors declared no competing interests.

Applies directly to

Experimental chronic GVHD in mice only.

Preliminary appraisal framework

Not reported in this record.

Preliminary risk-of-bias status

Not reported in this record.

Appraisal rationale

Not reported in this record.

No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.

Provenance

Sources and record status

Identifiers

PMID: 28374556 · DOI: 10.1111/jcmm.13155

Publisher access

Free full article on PubMed Central.

Extraction basis

PubMed metadata and complete PubMed Central article; full-text extraction checked 8 August 2026.

Record revision

2026-08-10